Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nicotine cessation program.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: 18 years — 80 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Close to 20% of cancer patients currently use nicotine products. Nicotine use in breast cancer patients is associated with poorer overall outcomes, including worsened survival and increased surgical complications. Nicotine cessation is rarely addressed in breast cancer patients at the time of diagnosis and may be a missed opportunity to optimize patient outcomes. Patients that use nicotine products are not offered reconstruction at time of mastectomy or oncoplastics at the time of lumpectomy, which can be emotionally distressing in women with breast cancer. Reconstruction could be an additional motivating factor in nicotine cessation success. This study aims to evaluate the feasibility of a nicotine cessation program designed by Area Health Education Center (AHEC) in the target population. The study is designed to test the acceptability, and preliminary efficacy of a formal nicotine cessation program in women actively using nicotine products with breast cancer recommended for reconstructive or oncoplastics surgery.
Interventions
- Behavioral Nicotine cessation program
Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant therapy (i.e. chemotherapy or hormonal/endocrine therapy) prior to surgery or over 4-6 weeks if not receiving neoadjuvant therapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant therapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
Primary outcome measures
- Feasibility [Time frame: 12-24 weeks (if receiving neoadjuvant therapy prior to surgery) or 4-6 weeks (if not receiving neoadjuvant therapy prior to surgery)]
Secondary outcome measures (6)
- Acceptability [Time frame: 10-30 weeks]
- Preliminary efficacy [Time frame: 10-30 weeks]
- Short-term impact on nicotine cessation [Time frame: 10 days prior to surgery]
- Long-term impact on nicotine cessation [Time frame: 12 months postoperatively]
- Patient engagement [Time frame: 12-24 weeks (if receiving neoadjuvant therapy prior to surgery) or 4-6 weeks (if not receiving neoadjuvant therapy prior to surgery)]
- Surgical procedure [Time frame: At surgery]
Eligibility criteria
Inclusion criteria
- Adults ≥ 18 years of age and ≤ 80 years of age.
- Women who are diagnosed with Stage 0 - 3 breast cancer confirmed by biopsy
- Women who have been recommended to have reconstruction at time of mastectomy or oncoplastics at time of lumpectomy
- Participants who actively use nicotine products defined as any self-reported nicotine use within the past month
- Participant agrees to comply with all the study-related procedures.
Exclusion criteria
- Patients not eligible for reconstruction or oncoplastics for other reasons including BMI>35 or inflammatory breast cancer or based on surgeon discretion.
- Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- Patients unable to complete the sessions because of language, travel or technology barriers
- Patients already actively participating in another cessation program
- Patients who are pregnant.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of Florida — Gainesville
Identifiers
NCT: NCT06461650 · UF-BRE-013 · IRB202401102